Cost-effectiveness analysis of Shexiang Baoxin Pill (MUSKARDIA) as the add-on treatment to standard therapy for stable coronary artery disease in China.

Jie PanPing-da PingWei WangJia-Meng ZhouWen-Tao Zhu

Published in: PloS one (2024)

This is the first study to evaluate the cost-effectiveness of SBP in the treatment of CAD. In conclusion, SBP as an add-on treatment to standard therapy appears to be a cost-effective strategy for CAD in Chinese patients.

Keyphrases

coronary artery disease
stem cells
heart failure
type diabetes
cardiovascular disease
cardiovascular events
percutaneous coronary intervention
acute coronary syndrome
mesenchymal stem cells